12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ADX71149: Phase IIa started

In June, Johnson & Johnson's Janssen Pharmaceuticals Inc. unit began a double-blind, placebo-controlled, international Phase IIa trial evaluating 25-150 mg oral ADX71149 twice daily for 8 weeks as an adjunct to antidepressants in 94 MDD patients with anxiety symptoms....

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >